BSGI Offers Clarity of Breast Tumor Chemotherapy | Radiology
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange

Gold Standard

Radiology BSGI Offers Clarity of Breast Tumor Chemotherapy

BSGI Offers Clarity of Breast Tumor Chemotherapy

Radiology News - Radiology
Gamma Imaging (BSGI) accurately estimates the size of cancerous breast tumors within 5mm- explained in a new study, presented at the American Society of Breast Surgeons Annual Meeting in Las Vegas.  
BSGI is a molecular breast imaging technique (MBI). It improves breast cancer detection and aid the treatment of patients' breast tissue that are tough to detect. The research study was conducted by Dr. Christine Teal, Chief of Breast Surgery at The George Washington University Hospital in Washington, D.C.and her team. 

12 patients were involved in the study where, it was determined that, BSGI can accurately diagnose tumor response to neoadjuvant chemotherapy. A definite measurement of every single tumor after neoadjuvant chemotherapy before the operation was conducted was facilitated by BSGI. The analysts also derived that the accuracy of BSGI in their study was higher compared to the earlier report on physical inspection, mammography, ultrasound, MRI or F-18 PET imaging in other studies. These outcomes confirmed that BSGI could successfully estimate the size of the cancerous tumors to within 5mm, and help patient care with more authentic operative access. Dilon 6800®, a high-resolution, small field-ofview gamma camera optimized to perform BSGI study. 

The patient acquires a pharmaceutical detecting agent soaked by all the cells in the body. The affected cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as dark spots on the BSGI image due to their advanced rate of metabolic activity. 

According to Dr. Teal, “BSGI provides excellent specificity and sensitivity in determining initial tumor size as well as accurately reflects response to neo-adjuvant chemotherapy. This allows for more precise surgical planning prior to definitive surgical procedure in this population of women.”

Source: Dilon Diagnostics

 

 

 

 

Related Articles